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Abstract
Background—Clinical and functional imaging evidence suggests that cerebellar dysfunction
occurs in essential tremor (ET). In recent postmortem studies, we documented increased numbers of
torpedoes (Purkinje cell axonal swellings) in ET patients without Lewy bodies. Purkinje cell loss,
however, has never been rigorously assessed.
Objective—To quantitatively assess the number of Purkinje cells in brains of ET patients and
similarly aged controls.
Methods—Postmortem cerebellar tissue was available in 14 ET cases (6 with Lewy bodies and 8
without Lewy bodies) and 11 controls. Calbindin immunohistochemistry was performed on paraffin
sections of the cerebellum. Images were digitally recorded and blinded measurements of the number
of Purkinje cells per millimeter of cell layer (linear density) were made.
Results—Purkinje cell linear density was inversely correlated with age (r=-0.53, P=.006) and
number of torpedoes (r=-0.42, P=.04). Purkinje cell linear density differed by diagnosis (mean [SD],
controls, 3.46 [1.27] cells/mm; ET cases with Lewy bodies, 3.33 [1.06] cells/mm; and ET cases
without Lewy bodies, 2.14 [0.82] cells/mm; P=.04), with the most significant difference between ET
cases without Lewy bodies and controls, where the reduction was 38.2% (P=.04). In an adjusted
linear regression analysis that compared ET cases without Lewy bodies with controls, decreased
linear density (outcome variable) was associated with ET (!=.56, P=.03).
Conclusions—We demonstrated a reduction in Purkinje cell number in the brains of patients with
ET who do not have Lewy bodies. These data further support the view that the cerebellum is
anatomically, as well as functionally, abnormal in these ET cases.
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ESSENTIAL TREMOR (ET) IS A common and often progressive neurological disease, with
a prevalence of approximately 4% among adults aged 40 years and older.1-3 There have been
few postmortem ET studies.4-9 While these studies did not reveal consistent structural
abnormalities, several noted mild to marked loss of Purkinje cells. However, as none of these
were controlled studies (ie, there were no control brains for comparison), it was not clear
whether this finding represented a normal age-related change.
Clinical and functional imaging evidence suggests that cerebellar dysfunction occurs in ET,
10-13 and magnetic resonance spectroscopic imaging suggests that metabolic abnormalities
occur; these abnormalities might represent neuronal loss.4 In several recent postmortem
studies,14,15 we documented a marked increase in the number of Purkinje cell axonal swellings,
torpedoes, in ET. In one ET case, the pathologic changes in the cerebellum were more manifest,
with degenerative changes in the dentate nucleus.15 However, quantification of Purkinje cells
was not rigorous in these earlier reports,14,15 thus it was not clear whether these torpedoes in
the ET cerebellum were accompanied by Purkinje cell loss. To address this question, we
quantitatively assessed cerebellar Purkinje cell numbers by measuring linear cell densities in
ET patients' brains and controls' brains. This is the only study, to our knowledge, that has
attempted to do so.
Announcement
Trial Registration Required. In concert with the International Committee of Medical
Journal Editors (ICMJE), Archives of Neurology will require, as a condition of consideration
for publication, registration of all trials in a public trials registry (such as
http://ClinicalTrials.gov). Trials must be registered at or before the onset of patient
enrollment. This policy applies to any clinical trial starting enrollment after July 1, 2005.
For trials that began enrollment before this date, registration will be required by September
13, 2005, before considering the trial for publication. The trial registration number should
be supplied at the time of submission.
For details about this new policy, and for information on how the ICMJE defines a clinical
trial, see the editorial by DeAngelis et al in the January issue of Archives of Dermatology




This study was conducted at the Essential Tremor Centralized Brain Repository (ETCBR) at
Columbia University, New York, New York. Postmortem tissue from the cerebellum was
available in 14 ET cases (5 were not included in earlier reports14,15) and 11 control brains (1
was not included in earlier reports14,15). The ET cases included 5 archival and 9 prospectively
collected cases. All brains were well characterized by the New York Brain Bank, Columbia
University Medical Center, and underwent complete neuropathologic assessment (among other
things, this included alphasynuclein-stained sections of the dorsal vagal nucleus, locus
ceruleus, and substantia nigra pars compacta; New York Brain Bank Web site,
http://nybb.hs.columbia.edu) and determination of any pathologic findings. Each brain was
rated by Braak and Braak staging16 for Alzheimer neurofibrillary changes and by Consortium
to Establish a Registry for Alzheimer's Disease (CERAD) staging17 for plaque pathology.
The 5 archival ET cases comprised 2 from the New York Brain Bank, 2 from the Honolulu-
Asia Aging Study, and 1 from the University of Kansas Brain Bank. In 3 of the 5 archival ET
cases, the treating neurologists, all of whom were neurologists specializing in movement
Axelrad et al. Page 2






















disorders, had assigned the ET diagnoses while the patients were alive. The ETCBR
neurologists obtained clinical records (office records from treating internists and neurologists)
to acquire data about tremor type, distribution, severity, and duration; coexistence of other
medical and neurological disorders; and medications. Using these records, an ETCBR
neurologist who specialized in movement disorders confirmed their diagnoses post mortem
using ETCBR diagnostic criteria, which were modeled after the diagnostic criteria for ET
proposed in the Consensus Statement of the Movement Disorder Society.18 The ETCBR
criteria were as follows: (1) bilateral action tremor of the arms for 5 or more years with a
diagnosis of ET during life, (2) head tremor or moderate or severe action tremor of at least one
hand (ie, tremor resulted in difficulty with 2 or more activities of daily living or required
medication), and (3) action tremor was not the result of other movement disorders,
hyperthyroidism, other medical conditions, or medications.14 During serial assessments, the
2 archival ET patients from the Honolulu-Asia Aging Study had repeatedly demonstrated
moderate to severe bilateral hand tremor in the absence of parkinsonism and other etiologies
but had not received a diagnosis of ET during their lives.
The 9 prospectively collected ET cases were all recruited through International Essential
Tremor Foundation newsletters. International Essential Tremor Foundation members who
were interested in brain donation responded to these quarterly brain bank advertisements.19
Each patient had ET diagnosed by his or her treating neurologist. To reconfirm these diagnoses,
members interested in brain donation were mailed standardized clinical questionnaires (which
included screening questions for Parkinson disease and spinocerebellar ataxia and family
history information) and written instructions to assist them in the preparation of a videotaped
neurological examination. Based on the instructions, they prepared a 30-minute videotaped
neurological examination, following the sequential instructions. The videotape included (1) a
full tremor demonstration (assessments of postural arm tremor, rest tremor [while seated and
while walking], kinetic tremor [while pouring, using a spoon, drinking, drawing a spiral, and
performing the finger-nose-finger maneuver with each hand], head tremor, chin tremor, and
voice tremor), (2) elicitation of parkinsonism with items from the motor portion of the Unified
Parkinson's Disease Rating Scale20 (facial expression and blink frequency while seated and
facing the camera, speech, rest tremor in each limb evaluated while seated and while walking,
rapid alternating movements [opening and closing each hand, pronating and supinating each
hand, and foot taps], arising from a chair to a standing position, standing with arms at the sides,
and walking for 60 seconds), and (3) an assessment of cerebellar signs with items taken from
the International Cooperative Ataxia Rating Scale21 (as noted, speech, 3 types of rapid
alternating movements, finger-nose-finger maneuver, drawing spirals with each hand, sitting,
stance, and gait). Using these records, an ETCBR neurologist who specialized in movement
disorders confirmed patients' diagnoses after death using ETCBR diagnostic criteria, which
were modeled after the criteria proposed in the Consensus Statement of the Movement Disorder
Society.18
Ten of 11 control brains were obtained through the New York Brain Bank. These were
individuals who had been enrolled as healthy elderly controls in the Alzheimer's Disease
Research Center or the Washington Heights Inwood Columbia Aging Project; they were
followed up prospectively with serial neurological assessments, remaining free of a diagnosis
of Alzheimer disease, ET, or Parkinson disease during life and not having significant
neuropathologic changes on postmortem evaluation. These 10 controls were selected for this
study based on their age (ie, they were frequency matched to ET participants based on age).
One control brain was obtained from the Honolulu-Asia Aging Study as a match for the 2 cases
from that study. This person had remained free of a neurological diagnosis during life.
Demographic and clinical information was collected on all cases and controls (from treating
physicians and also directly from the patient in prospectively collected cases). Heavy ethanol
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use was defined as a man consuming a mean of 4 or more standard drinks (15 mL of absolute
ethanol) per day or a woman consuming 3 or more standard drinks per day.22 Lifetime exposure
to medications known to cause cerebellar damage (eg, lithium and diphenylhydantoin) was
assessed.
PROCESSING TISSUE
Postmortem interval (PMI) was the number of hours between death and placement of the brain
in a cold room or on ice. For the current analyses, the cerebellum was our primary region of
interest because many studies have implicated its involvement in ET.10-15,23 A 3×20×25-mm
parasagittal tissue block that came from the same region of the neocerebellum in cases and
controls and included, in continuity, the cerebellar cortex, white matter, and dentate nucleus,
was harvested from each brain and then immersion fixed in buffered formalin, 10%.14,15
Paraffin sections (7 µm) were stained with Luxol fast blue and hematoxylin and eosin for
general tissue survey and quantification of torpedoes.
IMMUNOHISTOCHEMISTRY
Paraffin sections measuring 7 µm × 20 mm × 25 mm were placed on subbed glass slides.
Calbindin immunoreactivity was evaluated using a primary mouse monoclonal antibody to
calbindin D-28K (clone CG-955, Sigma-Aldrich Corp, St Louis, Missouri). Sections were
deparaffinized, incubated in proteinase K, 0.1% (Sigma-Aldrich Corp), at room temperature
for 10 minutes, washed, and then treated with hydrogen peroxide, 3%. All washes used
phosphate-buffered saline. Secondary antibody treatment with antimouse IgG was visualized
using avidin-biotin peroxidase complex (Vectastain Elite ABC; Vector Laboratories,
Burlingame, California) with the chromogen 3,3-diaminobenzidine (DAB Substrate Kit,
Vector Laboratories). For each brain, staining was also performed in the absence of primary
antibody to be certain no nonspecific 3,3-diaminobenzidine reaction product was present.
ASSESSMENT OF PURKINJE CELL LINEAR DENSITY AND TORPEDOES
Sections were examined using a microscope with an ×4 objective. A color charged-coupling
device video camera, a video capture card, and Videum 2.9.3a (Winnov, Santa Clara,
California) Windows software were used to digitally record microscopic images. These were
analyzed to quantify Purkinje cell linear density by a trained technician who was blinded to all
clinical information and diagnoses. Slides were photographed with the dentate situated on the
right and the folia branches extending leftward. For photographing, folia were labeled
numerically and the 2 folia located most central in the slide were selected. Within each of these
2 folia, 4 smaller subregions consisting of the 2 most distal peaks (gyri) and the 2 most distal
troughs (sulci) were chosen so that there were 8 subregions per participant. The photographs
were arranged sequentially and the Purkinje cell layer was measured using Scion Image
Software for Windows Beta 4.0.2 (Scion Corporation, Frederick, Maryland). Purkinje cells
with visible nuclei were counted. Purkinje cell layer length and the number of nucleated
Purkinje cells were summed from each of the 8 sub-regions and represented linear cell density
(ie, Purkinje cells per millimeter of Purkinje cell layer). To assess the test-retest reliability of
these estimates of Purkinje cell linear cell density, the trained tester repeated the analysis after
several months on newly prepared and stained sections from 3 participants and obtained similar
results (correlation between Purkinje cell linear densities measured at 2 different sessions,
r=0.98). We also conducted a study in which we examined the consistency of our counts across
different sections from the same tissue block. In 5 participants, the trained tester performed the
same analysis on 2 different sections from the same block. Section-section agreement was high
(r=0.99, with a mean 7.3% section-section difference in estimates of Purkinje cell linear
density). Based on this high level of agreement, measurements were made on one cerebellar
section per participant, though, as described, 8 regions were examined per section. To quantify
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torpedoes, the hematoxylin-eosin-stained 20×25-mm section was used and the number of
torpedoes in the entire section was counted.
STATISTICAL ANALYSIS
In a previous study,14 ET cases demonstrated 2 patterns of pathologic changes: ET cases with
Lewy bodies vs ET cases without Lewy bodies. As reported previously,14 these Lewy bodies
were primarily found in the locus ceruleus. The number of cerebellar torpedoes was
significantly increased in the ET cases without Lewy bodies.14 This pathologic subdivision of
ET cases was also applied in the current analyses and all cases fell into 1 of these 2 categories.
Statistical analyses were performed using SPSS, version 13.0 (SPSS Inc, Chicago, Illinois).
We used "2 tests, t tests, and analysis of variance to compare ET cases with controls in terms
of age, sex, and other characteristics. Pearson coefficients (r) were used to assess correlations
between continuous, normally distributed variables. Purkinje cell linear densities were
compared among diagnostic groups using t tests and analysis of variance. In an unadjusted
linear regression analysis, in which the dependent variable was Purkinje cell linear density, we
compared diagnostic groups. This model was then adjusted for age, sex, and PMI. We also
tested for a trend in Purkinje cell linear density using a similar linear regression model that
included all 3 diagnostic groups (controls [reference group], ET cases with Lewy bodies, and
ET cases without Lewy bodies). In some analyses, ET cases were stratified into those with 10
or more torpedoes vs those with fewer than 10.
RESULTS
The 14 ET cases were similar to the 11 controls in terms of age, sex, race, PMI, and brain
weight. None of the cases or controls had a history of heavy ethanol use or exposure to a
medication known to cause cerebellar damage (Table). The mean number of torpedoes was 10
times higher in ET cases without Lewy bodies (mean [SD], 10.8 [6.3]) than in controls (1.2
[1.1]). One of the ET cases with Lewy bodies had Alzheimer disease (CERAD plaque score,
C; Braak and Braak stage, V).
Purkinje cell linear density differed by diagnosis (mean [SD], controls, 3.46 [1.27] cells/mm
[n=11]; ET cases with Lewy bodies, 3.33 [1.06] cells/mm [n=8]; and ET cases without Lewy
bodies, 2.14 [0.82] cells/mm [n=6]; F=3.71; P=.04). In this analysis, there was a significant
38.2% difference (P=.04) between ET cases without Lewy bodies and controls (Figure 1 and
Figure 2). Combining all 14 ET cases into one group, mean Purkinje cell linear density was
2.64 (SD, 1.09) cells/mm (ie, 23.5% lower than that of controls), with a P value for the
casecontrol comparison that was of marginal significance (t=1.72, P=.1).
In our sample of 14 ET cases and 11 controls, Purkinje cell linear density was inversely
correlated with age (r=-0.53, P=.006); with every 1-year increase in age, Purkinje cell linear
density declined by 0.08 cells/mm. Purkinje cell linear density was also inversely correlated
with the number of torpedoes (r=0.42, P=.04); with each 1-torpedo increase, Purkinje cell
linear density declined by 0.08 cells/mm. Purkinje cell linear density did not correlate with
PMI (r=0.24, P=.33), CERAD plaque score (r=0.60, P=.78), Braak and Braak stage (r=-0.32,
P=.14), or brain weight (r=0.34, P=.11), nor did it differ between men and women (neither in
the total sample nor when stratified by diagnosis).
In an unadjusted linear regression analysis that compared ET cases without Lewy bodies (n=8)
with controls (n=11), Purkinje cell linear density (outcome variable) was lower in ET cases
without Lewy bodies than in controls (!=.66, P=.02). Adjusting in this model for age, sex, and
PMI, the association remained significant (!=.56, P=.03). Adjusting for brain weight in the
same model did not change the results either (!=.56, P=.03).
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In an unadjusted linear regression analysis that included all participants (ie, a test for trend),
Purkinje cell linear density (outcome variable) was associated with diagnosis (controls
[reference group], ET cases with Lewy bodies, and ET cases without Lewy bodies; test for
trend, !=.64, P=.02) After adjusting for age, sex, and PMI, this association remained significant
(test for trend !=.56, P=.03). Starting with the same adjusted model and further adjusting for
brain weight or for Braak and Braak stage and CERAD plaque score did not change the results.
Removing the one ET case with Alzheimer disease did not change these results either.
We further stratified ET cases without Lewy bodies into those with 10 or more torpedoes (n=3)
vs those with fewer than 10 torpedoes (n=5). Mean Purkinje cell linear density was 1.42 (SD,
0.41) cells/mm in ET cases with 10 or more torpedoes, which was 59.0% lower than that of
controls (3.46 [SD, 1.27] cells/mm, P=.04). Mean Purkinje cell linear density was 2.57 (SD,
0.69) cells/mm in ET cases with fewer than 10 torpedoes. This was 25.7% lower (P=.43) than
that of controls (Figure 3).
COMMENT
This study has sought to further elucidate the pathogenesis of ET. Converging clinical and
neuroimaging data suggest the presence of cerebellar dysfunction in ET,10-15,23 and recent
postmortem studies have shown the existence of microscopic changes (Purkinje cell swellings)
in the cerebellum of most ET cases.14,15 The loss of Purkinje cells in the ET cerebellum rarely
has been commented on. However, a quantitative comparison of the number of Purkinje cells
in ET vs control brains has never been undertaken. Thus, the actual loss of Purkinje cells in a
subset of ET brains has not been formally assessed. In this study, we demonstrated that ET
patients without Lewy bodies had a significant reduction in the number of Purkinje cells
compared with a similarly aged control group.
In the older literature, authors occasionally commented briefly on the presence of Purkinje cell
loss in some of their ET cases. In one case, this loss was mild,7 whereas in 3 others it was more
marked.4-6 In a more recent study, Rajput et al9 commented on the presence of mild Purkinje
cell loss in 2 of their 20 ET cases.9 However, as mentioned, none of these studies performed
a formal quantification of Purkinje cell number and none compared these ET case brains with
control brains. Although we demonstrated a reduction in Purkinje cells in ET patients without
Lewy bodies, the reduction was modest (approximately 40%), which is less than that which
has been reported in patients with multiple system atrophy (60%-75% in postmortem studies).
24,25
We found that Purkinje cell linear density was inversely associated with age. With healthy
aging, the loss of Purkinje cells has been estimated to be 2.5% to 5.0% per decade.26-28 This
underscores the importance of the use of a healthy age-matched comparison group. It also lends
validity to our method of assessing Purkinje cell linear density (ie, failure to demonstrate this
association between age and Purkinje cell linear density would have raised concerns about the
validity of our linear density data).
We also found an inverse correlation between linear density of Purkinje cells and the number
of torpedoes. This further corroborates the validity of our measure of linear density of Purkinje
cells and suggests that torpedoes and Purkinje cell loss may be concomitant features of
cerebellar degeneration.
As in our previous study,14 ET cases could be divided into groups based on the presence or
absence of Lewy bodies. Essential tremor patients with Lewy bodies have them (Lewy bodies)
in the locus ceruleus and have a relatively low number of torpedoes, whereas ET patients
without Lewy bodies have increased numbers of torpedoes and, as we have now demonstrated,
a reduction in Purkinje cell number. Essential tremor patients with Lewy bodies had a similar
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Purkinje cell linear density as controls, further supporting the notion that there are pathologic
subtypes of ET.14 This pathologic subdivision of ET cases seems to indicate, as has been
suggested recently,29,30 that ET may be a family of diseases unified by the presence of action
tremor that is further characterized by etiological, clinical, and pathologic heterogeneity. The
clinical features that distinguish ET cases with Lewy bodies vs without are not established and
are currently under investigation. That some cases of ET have Lewy bodies as their primary
pathologic manifestation converges with a wealth of clinical data that center on the apparent
links between ET and Parkinson disease.31-38 The development of Parkinson disease has often
been described in ET patients,31,32,38 and ET-like action tremor is more common in Parkinson
disease families than in control families,34 again, further demonstrating the links between ET
and Lewy body disease. Whether ET patients with Lewy bodies are more prone to develop
Parkinson disease than their counterparts without Lewy bodies is currently unknown.
The mean Purkinje cell linear density that we report for our controls was 3.46 (SD, 1.27) cells/
mm. A range of mean linear Purkinje cell densities has been reported among healthy controls,
with some studies reporting results as low as 1.6 cells/mm39 and others in the range of 2 to 3
cells/mm (2.36 cells/mm25 and 2.5-3 cells/mm40), 4 to 5 cells/mm (4.49 cells/mm,41 4.6 cells/
mm,42 and 4.6 cells/mm43), 6 to 7 cells/mm (6.9 cells/mm44 and 7.1 cells/mm45), and 10 to
11 cells/mm.46 This variability is likely caused by a variety of issues, including technical
factors, such as fixation shrinkage, staining techniques, and section thickness, but also by
demographic differences including age. Our numbers are within the reported range.
This study had limitations. First, we sampled only one region of the cerebellar hemisphere.
This does not diminish the validity of our findings. However, it remains to be demonstrated
that these findings can be generalized to other regions of the ET cerebellum (eg, vermis).
Second, a stereological assessment of Purkinje cell number would have allowed for greater
precision as well as a randomized assessment. Such a study is currently under way. Third, while
the number of participants seems relatively small, this actually represents the second largest
series of reported ET cases, with all except one previous study9 reporting the results of only 1
or 2 cases. With our sample size, statistically significant findings were demonstrable. The
strengths of this study include its use of a standardized, blinded, quantitative assessment of
Purkinje cells and control brains for comparison. In addition, we could adjust for a number of
important potential confounders (eg, age and PMI). Finally, we were able to examine the
associations between linear density of Purkinje cells and other pathologic changes in the
cerebellum (ie, torpedoes).
In summary, we demonstrated a reduction in Purkinje cell number in ET patients without Lewy
bodies. These data further support the view that the cerebellum is functionally and structurally
abnormal in these ET cases.
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Purkinje cell linear density differed by diagnosis (mean [SD], controls, 3.46 [1.27] cells/mm;
essential tremor [ET] cases with Lewy bodies,3.33 [1.06] cells/mm; and ET cases without
Lewy bodies, 2.14 [0.82] cells/mm; F=3.71; P=.04), with a 38.2% difference between ET cases
without Lewy bodies and controls (P=.04). Bars show SE.
Axelrad et al. Page 10























Representative photographs (original magnification ×40) of calbindin immunohistochemistry
on similar cerebellar folia sections from 2 individuals: an 84-year-old healthy control (A and
B) and a 90-year-old patient with essential tremor (C and D). It is evident that whereas 12
Purkinje cells are seen in the Purkinje layer of the control (A, 4 denoted by arrows), only 2 are
seen in the patient with essential tremor (C, arrows). Numerous Purkinje cell bodies are densely
stained in the control (B), whereas there are only 2 evident in the patient with essential tremor
(D). The Purkinje cell linear density was 4.29 cells/mm in the control and 1.27 cells/mm in the
patient with essential tremor.
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We stratified essential tremor (ET) cases without Lewy bodies into those with 10 or more
torpedoes (n=3) and those with fewer than 10 torpedoes (n=5). Purkinje cell linear density was
lower in those with 10 or more torpedoes (mean [SD], 1.42 [0.41] cells/mm or 59.0% lower
than that of controls) than in those with fewer than 10 torpedoes (2.57 [0.69] cells/mm or 25.7%
lower than that of controls). For comparison of those with 10 or more vs fewer than 10
torpedoes, t=2.59, P=.04. Bars show SE.
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Table
Demographic, Clinical, and Pathologic Features of Essential Tremor (ET) Cases and Controls
Characteristic All ET Cases




No. of cases 14 6 8 11
Mean age (SD), y 88.0 (7.7) 89.0 (4.2) 87.3 (9.8) 84.6 (8.8)
Male sex, No. (%) 7 (50) 4 (66.7) 3 (37.5) 7 (63.6)
White race, No. (%) 12 (85.7) 4 (66.7) 8 (100) 10 (90.9)
Mean postmortem
interval (SD), h 6.7 (3.4) 8.9 (3.1) 5.7 (3.3) 7.3 (9.3)
Mean brain weight
(SD), g 1169.7 (335.8) 1241.9 (133.9) 1115.5 (434.5) 1238.1 (129.2)
History of heavy
ethanol use, No. (%) 0 0 0 0
Treated with a
medication for ET,
No. (%) 10 (74.1)a 5 (83.3)a 5 (62.5)b 0
Lifetime exposure to a
medication known to
cause cerebellar
damage, No. (%) 0 0 0 0
Mean duration of
tremor (SD, range), y 27.9 (21.2, 5-65) 26.0 (27.8, 5-65) 29.1 (18.0, 9-57) Not applicable
Family history of ET,
first-degree relative,




No. (%) 0 0 0 0
Mean No. of
torpedoes (SD) 8.2 (6.3)b 4.8 (4.8) 10.8 (6.3)a 1.2 (1.1)
Mean Purkinje cell
linear density (SD),
cells/mm 2.64 (1.09) 3.33 (1.06) 2.14 (0.82)c 3.46 (1.27)
a
P < .001 compared with controls
b
P < .01 compared with controls.
c
P < .05 compared with controls.
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